Avoro Capital Advisors’s Akero Therapeutics AKRO Stock Holding History

Avoro Capital Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,955,555	Closed	-$188M	–	35
2025 Q3	$188M	Buy	3,955,555 +455,555	+13%	+$22.1M	2.43%	14
2025 Q2	$187M	Buy	+3,500,000	New	+$159M	3.27%	10
2023 Q4	–	Sell	-555,555	Closed	-$28.1M	–	43
2023 Q3	$28.1M	Buy	+555,555	New	+$25.9M	0.44%	26

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Avoro Capital Advisors's AKRO Position: Q4 2025 in Review

Avoro Capital Advisors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 3,955,555 shares — an estimated $188M sold.

Avoro Capital Advisors first reported a position in AKRO in Q3 2023 and held it in 3 quarters. The position peaked at $188M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Avoro Capital Advisors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Avoro Capital Advisors sold 3,955,555 Akero Therapeutics shares in Q4 2025, an estimated $188M.
Avoro Capital Advisors first reported a position in Akero Therapeutics in Q3 2023 and held it in 3 quarters.
Avoro Capital Advisors's Akero Therapeutics position peaked at $188M in Q3 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Avoro Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.